SC75741 comparator in RANKL-stimulated RAW264.7 cells
Cell-based study · Murine RAW264.7 cells stimulated with RANKL (50 ng/mL) [1]
Western blot comparison of RANKL alone, urolithin B (UB), SC75741, and UB plus SC75741. SC75741 lowered CTSK and NFATc1 expression; UB produced a greater reduction, and the combination produced a further reduction relative to either single agent. These are protein-expression endpoints, without a demonstrated direct binding mechanism or standalone bone-resorption outcome.
| Endpoint | Reported result | Reference |
|---|---|---|
| CTSK and NFATc1 protein expression normalized to β-actin | Relative protein expression Qualitative: lower with SC75741 than RANKL alone; lower with UB than SC75741; further reduced with UB + SC75741. No exact bar values extracted. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- SC75741 200 nM; UB 25 μM in the UB and combination groups; RANKL 50 ng/mL in all four groups (Figure 6E,F).
- Method
- Addition to RANKL-stimulated cell cultures followed by Western blot analysis.
- Co-treatment
- Separate RANKL-only, UB-only, SC75741-only, and UB + SC75741 groups; the combination result is not attributed to SC75741 alone.
- Reported limits
- Figure 6-specific treatment duration, vehicle and replicate number are not specified in the read main text/caption. The 200 nM value is a treatment concentration, not an IC50. Caption comparator symbols do not fully define the SC-only comparisons; no p-value is assigned here.
Methods and source locations
Compound reported in the paper: SC75741; Compound label in the paper: SC in Figure 6
Evidence for the named research compound in this cellular comparison; no inference of current lot validation or in vivo efficacy.
Section 2.6; Section 3.4, final paragraph; Figure 6B,E,F (image and caption)
CTSK and NFATc1 protein expression normalized to β-actin: Western blot with β-actin loading control; Figure 6B and densitometry in 6E,F. — Section 2.6; Section 3.4, final paragraph; Figure 6B,E,F (image and caption)